Search Results: 100% Pass Quiz High Pass-Rate Juniper - JN0-281 - Data Center, Associate (JNCIA-DC) New Braindumps Ebook š Open ā½ www.pdfvce.com š¢Ŗ enter ā” JN0-281 ļøā¬ ļø and obtain a free download š®Valid Exam JN0-281 Book
Excerpt from the Press Release: CAMBRIDGE, Mass.Ā andĀ WESTMINSTER, Colo.,Ā May 12, 2021Ā /PRNewswire/ —Ā Leap TherapeuticsĀ (Nasdaq:Ā LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, andFlagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that they have developed an image analysis RNAscopeĀ®Ā assay that is being used successfully for prospective patient enrollment in a clinical trial.…
Read More
“TrialStatās Unified eClinical Suite supports clinical trials for pharmaceuticals, vaccines, and medical devices by helping to capture and analyze millions of records during each trial. With FlashArray//X, TrialStat software gains the speed and real-time data access that researchers need.” Read the case study to find out why TrialStat has partnered with PureStorage and how the…
Read More
Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that Part A of the Phase 3 CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as an adjuvant treatment for patients with localized renal cell carcinoma (RCC) who have undergone full or partial removal of the kidney and who are at moderate or high risk…
Read More
From Clinical Leader comes a very timely article on the state of interoperability within clinical research Clinical Trials today can benefit tremendously as a result of the value produced from integration with EMR systems, leveraging Real World Data and Real World Evidence, and the adoption of eSource! “Three decades ago when I entered the profession…
Read More
Excerpt from the Press Release: BOSTON, July 29, 2020 /PRNewswire/ — Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors , today announced the presentation of safety and pharmacokinetic data from the Company’s recently completed PU-AD healthy volunteer Phase 1 study at the Alzheimer’s Association International Conference (AAIC 2020). PU-AD is Samus’…
Read More
Therapeutic Solutions International Continues Parallel Development of COPD Program in Conjunction with Pivotal Clinical Trial in COVID-19 Excerpt from the Press Release: OCEANSIDE, Calif.–(BUSINESS WIRE)–Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCellā¢ through induction of a specific cell type called āMyeloid Derived Progenitor Cellsā. In a series of…
Read More
The OBIOĀ® Capital Access Advisory Program (CAAPĀ®) operates downstream from existing entrepreneurship programs and focuses on accelerating technology commercialization, working towards Series A financing and strategic partnerships. OBIOās CAAPĀ® creates high value deal flow for both companies and investors, culminating with a presentation at the OBIOĀ® Investment Summitin 2024. Click the button below to read…
Read More
Excerpt from the article: A preclinical study in the US found that Gilead Sciencesā antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19. “The animals were infected with the novel coronavirus, SARS-CoV-2. Data announced by the National Institutes of Health (NIH) revealed a significant decrease in clinical disease and reduced lung…
Read More
The new test can diagnose the difficult-to-diagnose diseases in seconds with high certainty, beating out previous invasive methods like the spinal tap. Excerpt from the Press Release: Researchers from Ottawaās Carleton University have developed a rapid, saliva-based test that can reliably detect signs of Alzheimerās and Parkinsonās early on in the diseasesā development. The teamās…
Read More
First-in-human Phase 1a/1b clinical trial will evaluate orally available, RGT-61159 designed to selectively target MYB RNA and inhibit oncogenic MYB protein production Preclinical data supporting the clinical trial were recently presented at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) Excerpt from the Press Release: WOBURN, Mass., July 10, 2024 /PRNewswire/ — Rgenta…
Read More